Our inaugural presentation for the Breakthrough Speaker Series is Dr. Laurence Cooper, on behalf of ZioPharm Oncology, presenting "DNA Plasmids for the Genetic Engineering of Clinical-Grade T cells".

Speed, control and comparable results: these are among the foremost needs of contract development and manufacturing organizations (CDMOs) and our clients when it comes to plasmid DNA that will be used to support cell and gene therapy at a research, clinical and commercial level. As an early adopter of rapid sterility testing, Aldevron delivers on all three.

Challenging times require creative solutions. Especially now, when in-person contact is discouraged yet first-hand, observed information is critical, we all depend on fresh ways to think about how we provide access and insight.

Plasmids are essential for the development of viral vectors used to manufacture novel gene therapies and viral vaccines. Aldevron is supporting the innovation of drug developers in this space by providing standardized royalty-free, bulk AAV helper and lentiviral packaging plasmids for research and GMP production.

Sickle cell disease (SCD) is a common inherited blood disorder, affecting 70,000 to 80,000 Americans, with approximately 300,000 babies born each year worldwide with the disease.

This article was originally published in the October 26, 2018, edition of The Forum of Fargo-Moorhead and is republished here in its entirety.

This article was originally published in the September 23, 2018, edition of The Forum of Fargo-Moorhead and is republished here in its entirety.

Aldevron, a global provider of plasmid DNA and gene editing enzymes used to support novel cancer therapies, will be a Platinum sponsor of the 2017 Believe Ball organized by the Emily Whitehead Foundation. In its inaugural year, the Believe Ball will bring together T-Cell therapy patients and their families with the doctors, scientists, researchers, and others who helped develop this therapy.